REG - Medpal AI PLC - Trading Update

Medpal AIAnnouncement

Mon 10:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260105:nRSE6612Na&default-theme=true

RNS Number : 6612N  Medpal AI PLC  05 January 2026

5 January 2026

MedPal AI plc

("MedPal AI" or the "Company")

Trading Update - Pharmacy Operations

 

FDA Approves First Oral GLP-1 for Weight Loss

 

 

MedPal AI (AIM: MPAL), a UK-based digital health and artificial intelligence
("AI") company focused on health and wellness management, is pleased to
provide a trading update on its pharmacy operations for December 2025 and that
Novo Nordisk's Wegovy pill has now been approved by the FDA.

 

Trading Update - Pharmacy Operations

 

During December 2025, MedPal Limited processed 33,433 prescription orders
through its automated pharmacy operations, generating turnover of
approximately £325,000 at an average item value of £9.72. This represents
month-on-month growth of approximately 16% compared with November 2025's
28,789 prescriptions, a particularly strong performance given the shortened
trading month due to the Christmas period.

 

The continued scaling of prescription volumes reflects both the successful
integration of the NHS Distance Selling Pharmacy ("DSP") contract and growing
uptake of the Company's private weight loss service launched via
MedPal.clinic.

 

FDA Approves First Oral GLP-1 for Weight Loss

 

On 22 December 2025, the US Food and Drug Administration ("FDA") approved Novo
Nordisk's Wegovy pill (oral semaglutide 25mg), making it the first oral GLP-1
medication approved for weight management. This landmark approval represents a
paradigm shift in obesity treatment, offering patients a once-daily pill
alternative to weekly injections.

 

Clinical trials demonstrated that the oral formulation achieved weight loss of
up to 16.6% in adherent patients over 64 weeks, a result that is comparable to
the injectable form. The Directors believe this development will significantly
expand the addressable market for GLP-1 therapies, as many patients who are
reluctant to use injectable medications may now consider treatment. The oral
format removes barriers such as needle aversion and refrigeration
requirements, potentially bringing millions of new patients into the weight
management market.

 

MedPal.clinic, powered by Google's Vertex AI platform, is well positioned to
capitalise on this expanded market opportunity through its established
AI-powered triage and prescription fulfilment capabilities.

 

Jason Drummond, CEO of MedPal AI, said:

 

"We are delighted with MedPal Limited's continued strong performance,
achieving 16% month-on-month growth despite the Christmas period shortening
our effective trading days. Processing approximately 33,000 prescriptions in
December demonstrates the scalability and resilience of our automated
dispensing infrastructure.

 

" We were also pleased to hear of the FDA's approval of the first oral GLP-1
for weight loss, which we expect to be transformative for the industry. By
removing the barrier of injectable administration, we anticipate significant
expansion of the patient population seeking treatment. MedPal.clinic's
AI-first approach positions us to efficiently serve this growing market whilst
maintaining the highest standards of clinical safety and patient care."

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018). The Directors of the Company are
responsible for the contents of this announcement.

Enquiries:

 MedPal AI plc

 Jason Drummond, Chief Executive Officer     Via Square1 Consulting

 Cairn Financial Advisers LLP                +44 (0) 20 7213 0880

 Louise O'Driscoll/Jo Turner

 Clear Capital Markets Limited               +44 (0) 20 3869 6080

 Bob Roberts/ Nick Josh

 Square1 Consulting                          +44 (0) 20 7929 5599

 David Bick                                  +44 (0) 7831 381201

 

 

 

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven
wellness management. Its core app aggregates data from over 100 wearables and
health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile,
offering non-clinical, personalised lifestyle guidance through its AI wellness
coach. The Company is also developing conversational AI to provide
voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a
24/7 AI-powered automated pharmacy distribution centre, providing nationwide
NHS and private prescription services. The facility leverages advanced robotic
dispensing technology integrated with AI triage to deliver rapid,
cost-effective medication fulfilment with same-day and next-day delivery
capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for
a limited time, grant exclusive, zero-cost access to the MedPal AI app across
Epassi's network of 11M+ employees at major firms like Siemens and Volvo.
Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare
providers, businesses, and insurers, with potential use in insurance-linked
wellness programs to reduce premiums and drive new revenue through
institutional partnerships. The Company also has a partnership agreement with
Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTMZGGMGKLGVZM



            Copyright 2019 Regulatory News Service, all rights reserved